INTRODUCTION
Inositol 1,4,5-trisphosphate (InsP3) 3-kinase catalyses the phosphorylation of InsP,, which has been shown to mobilize intracellular Ca2+, to inositol 1,3,4,5-tetrakisphosphate (InsP4), a potential modulator of Ca2+ homoeostasis (Berridge and Irvine, 1989; Irvine, 1992) .
A cDNA clone encoding rat brain Ca2+/calmodulin (CaM)-sensitive InsP3 3-kinase has been isolated (Choi et al., 1990; Takazawa et al., 1990b) and expressed in Escherichia coli. The encoded protein of 459 amino acids has a calculated Mr of 50 868, equalling estimates made with the native rat brain enzyme (Takazawa et al., 1990a,b) . This enzyme is now referred to as InsP3 3-kinase A. Using the rat cDNA as a probe, Takazawa and colleagues isolated and expressed human InsP3 3-kinase A from a human hippocampus cDNA library (which presented 93 % sequence identity with the rat brain InsP3 3-kinase A amino acid sequence; Takazawa et al., 199 la) and a novel InsP3 3-kinase isoenzyme, referred to as InsP3 3-kinase B (Takazawa et al., 1991b) . The expressed InsP3 3-kinase B was more sensitive to Ca2+/CaM (i.e. stimulation factor of 7-10-fold) compared with expressed InsP3 3-kinase A (2-3-fold stimulated). Previous reports have suggested that InsP3 3-kinase might be a substrate for protein kinase C in human platelets (King and Rittenhouse, 1989) , rat hepatocytes (Biden et al., 1988) and human lymphocytes (Imboden and Pattison, 1987 (Takazawa et al., 1990a) in an incubation medium supplemented with protease inhibitors (50 jug/ml Pefabloc, 5 ,M leupeptin and 50 mM benzamidine). Apparent Km values were measured by using a non-linear least-squares curve-fitting program (Marquardt-Levenberg algorithm). Immune complexes were detected on Western blots, as described previously (Takazawa et al., 1990a) . Protein concentrations were measured as described by Petersen (1977) .
Expression of InsP3 3-kinase in E. coli
The expression of plasmid hh3 MB1 encoding InsP. 3-kinase B was performed as previously described (Takazawa et al., 199 for 4 h at 4°C (Takazawa et al., 1990a) . After electrophoresis, the gel was cut into 2.5-5 mm sections at 4 'C. Each slice was homogenized in 0.25 ml of an ice-cold extraction buffer containing 84 mM Hepes/NaOH (pH 7.4), 1 mM EDTA, 12 mM 2-mercaptoethanol, 250% (w/v) sucrose, 0.1 % Triton X-100, 50 ,g/ml Pefabloc, 5,M leupeptin, 50 mM benzamidine and 10 4ug/ml calpain inhibitors I and II. After 12 h at 4 'C, each fraction was centrifuged (13 000 g for 10 min) and the supernatant was assayed for activity in the presence of 1 % Triton X-100 and for 30 min. Recovery of enzyme activity was calculated by using the enzyme activity loaded on the gel (measured under similar conditions) as 1000%. (0-10,ul) and agitated for 1.5 h in a final volume of 50,1. A 25,l portion of Protein A-Sepharose prepared as described by Takazawa et al. (1990a) was added to each tube and incubation was continued for 1.5 h at 4 'C. After centrifugation, each supernatant was assayed for InsP3 3-kinase activity.
Purffication procedure for platelet InsP3 3-kinase Washed human platelets were prepared from 100 human blood units (Centre de Transfusion, Hopital Erasme, Brussels) after blood collection from healthy volunteers in I vol. of acid/citrate/ dextrose (1.5 % citric acid, 2.5 % trisodium citrate,2 % dextrose). Platelet-rich plasma was prepared by two successive centrifugations at 500 g for 15 min at room temperature. The plasma was carefully removed, and platelets were sedimented at 1800 g for 10 min before resuspending and washing in 10 ml of an isotonic buffer containing 10 mM Hepes/NaOH (pH 6.2), 2.7 mM KCl, 1 mM MgCl2, 135 mM NaCl, 12 mM NaHCO3, 5.5 mM dextrose, 0.3 % BSA and 13 mM trisodium citrate (Macphee et al., 1988) . After a further centrifugation at 1800 g for 10 min, the platelet pellet was resuspended [(1.5-2.0) x 109 platelets/ml] in an ice-cold buffer containing 50 mM Tris/HCl (pH 8.0), 1 mM EDTA, 10 % sucrose, 12 mM 2-mercaptoethanol, 50 ,ug/ml Pefabloc, 5,uM leupeptin, 50 mM benzamidine, 20 ,ug/ml pepstatin and 10 g/ml calpain inhibitors I and II. The platelets were lysed by three successive cycles of freeze-thawing, followed by centrifugation at 13 000 g for 10 min. The supernatant (58 ml of crude soluble fraction supplemented with 1 % Triton X-100) was applied in the presence of 0.5 mM CaCl2 to a 13 ml CaM-Sepharose column which had been equilibrated in 50 mM Tris/HCl (pH 7.5), containing 12 mM 2-mercaptoethanol, 0.2 mM CaCl2, 0.1 M NaCl, 0.50% Triton X-100, 50 ,tg/ml Pefabloc, 5,uM leupeptin, 10 ,g/ml calpain inhibitors I and II and 50 mM benzamidine (buffer A) at 4 'C. The column was washed with 130 ml of buffer A in which the concentration of NaCl was increased to 0.4 M. The column was finally washed with 70 ml of buffer A containing 2 mM EGTA in the absence of CaCl2 and Triton X-100. InsP3 3-kinase activity was eluted with 100 ml of buffer A containing 2 mM EGTA and 1 % Triton X-100 in the absence of CaCl2. The active fractions were pooled, concentrated with an Amicon cell to a final volume of 3 ml and immediately stored in batches at -70 'C.
Peptide synthesis and antibody production
The peptides LPGGPTGMARPGGARC, corresponding to part of the N-terminal region of the human InsP3 3-kinase A sequence [to raise an anti-(peptide A) antibody], and CPPGDRVGVQP-GNSR, corresponding to part of the N-terminal region of the human InsP3 3-kinase B sequence [to raise an anti-(peptide B) antibody] were synthesized at The Microchemical Facility at the Babraham Institute (U.K.). Briefly, peptide synthesis was performed by fluorenylmethoxycarbonyl chemistry. Peptides were purified by gel filtration in Bio-Gel P-2 gel (Bio-Rad) in 67 % acetic acid and conjugated to the purified protein derivative of tuberculin (Maloy, 1991) . A 1 mg portion of each antigen was injected three times into two rabbits (New Zealand White). By e.l.i.s.a., the anti-(peptide A) and anti-(peptide B) antibodies RESULTS Purification of human platelet Mr-69000-70000 insP3 3-kinase In order to identify human platelet InsP3 3-kinase by regeneration of enzyme activity after SDS/PAGE (Takazawa et al., 1990a) , the enzyme was purified by CaM-Sepharose affinity chromatography. InsP3 3-kinase activity from a crude soluble fraction of human platelets was shown to interact directly with CaMSepharose. This allowed separation of InsP3 5-phosphatase activity, all of which was detected in the flow-through (results not shown), from InsP3 3-kinase activity, which was subsequently eluted in the absence of Ca2+. The elution profile was optimized in the presence of a high detergent concentration (1 % Triton X-100) (Takazawa et al., 1990a) and different protease inhibitors, such as calpain inhibitors (I and II). A typical elution profile is shown in Figure 1 . We calculated the purification factor to be approx. 4500-fold, with a recovery of 75 % (Table 1) The Km for InsP3 of the purified enzyme was 2.0 ,uM (Figure 2 ). The Km for ATP was 2.5 mM at 5 ,tM InsP3 (results not shown).
Maximal stimulation by Ca2+/CaM of human platelet InsP3 3-kinase was at 1 ,uM CaM (at 1 or 10 ,uM free Ca2+): the enzyme exhibited a specific activity of 1.45 + 0.1 ,umol/min per mg of protein, and stimulation was approx. 17-fold when compared with the activity determined in the presence of 1 mM EGTA (Figure 3 ). Half-maximal stimulation was at 80 nM CaM at 1 or 10 uM free Ca2 . ldentfflcation of human platelet InsP3 3-kinase after SDS/PAGE Purified human platelet enzyme was identified by regeneration of enzyme activity after SDS/PAGE: enzyme activity was associated with a major Mr-67000-71 000 fraction (Figure 4a ). The Mr-67000-71000 InsP3 3-kinase was stimulated about 8-fold in the presence of 10 uM free Ca2+ and 0.1 ,uM CaM. A minor Mr-35000-38000 fraction could be identified in the gel: this lower- (a) Purified human platelet lnsP3 3-kinase (9.5,ug of protein and enzyme activity of 3.6 nmol/min that was applied on to the gel assayed as in Figure 4) Mr peak was much less Ca2+/CaM-sensitive (stimulation factor of only 2-fold in the separation shown in Figure 4a ). This Mr-35000-38000 fraction was observed three times in five experiments, but never represented more than 7 % of the Mr-67000-71 000 InsP3 3-kinase activity. The data are specific for the human platelet enzyme, as rat brain InsP3 3-kinase showed a major Mr-48000-51000 fraction (Figure 4b, and Takazawa et al., 1990a) . The Mr-48000-51 000 fraction of rat brain was stimulated only 2-fold by Ca2+/CaM. A sample of purified enzyme was separated by SDS/PAGE (Figure 5a ): the two active Mr-67000-71 000 fractions were associated with a silver-stained band which had an apparent Mr of 69000-70000 (Figure 5b) . The silver-stained Mr-50000-51 000 band did not correspond to any InsP3 3-kinase activity,, as.
Crude fraction from rat brain (lanes 1 and 4; 8 ,ug of protein, with an activity of 0.17 nmol/min at 5 ,uM InsP3), purified human platelet lnsP3 3-kinase (lanes 2 and 5; 1.7 ug, with an activity of 0.58 nmol/min) and crude bacterial lysate of recombinant InsP3 3-kinase B (lanes 3 and 6; 14,ug, with an activity of 0.21 nmol/min) were subjected to SDS/PAGE (8% gels) and then electrophoretically transferred to nitrocellulose. The blots were incubated with anti-(peptide A) serum diluted 1 :500 (lanes 1-3) or with anti-(peptide B) serum diluted 1 :500 (lanes 4-6). The Mr-50000 InsP3 3-kinase A (50 kDa) and the Mr-63000 lnsP3 3-kinase B (63 kDa) are designated by arrows. The Mr-66000 band was also recognized by the pre-immune serum (see identified by regeneration of enzyme activity (Figure 5a ). When the two active fractions of Mr-67000-71 000 ( Figure Sa) were pooled and re-applied on to a second SDS gel, a single Mr-69 000-70 000 silver-stained band could be seen, with no evidence of proteolysis (Figure 5c ).
Immunological characterization of human platelet InsP3 3-kinase Anti-(rat brain Mr,50000 InsP3 3-kinase A) serum (Takazawa et al., 1990a) (Figure 6 , lane 1), as previously shown with anti-(Mr-50000 rat brain InsP3 3-kinase A) serum (Takazawa et al., 1990a) . Moreover, anti-(peptide A) serum was unable to recognize human platelet enzyme and human brain InsP3 3-kinase B (Figure 6, lanes 2 and 3) . On the other hand, anti-(peptide B) serum recognized human brain InsP3 3-kinase B as an Mr-63000 protein ( Figure 6 , lane 6). In contrast, the serum was unable to recognize rat brain InsP3 3-kinase A and human platelet InsP3 3-kinase isoenzyme (Figure 6 , lanes 4 and 5). The blots, incubated with the corresponding preimmune sera (dilution 1: 500), did not reveal any signal, except the Mr-66000 band in Figure 6 , lane 1 (results not shown). of the enzyme(s) in rat liver (Conigrave et al., 1992) and pig aortic smooth muscle (Yamaguchi et al., 1988) We report here the purification and characterization of a novel high-Mr (69000-70000) InsP3 3-kinase isoenzyme in human platelets. This was shown by both regeneration of enzyme activity after SDS/PAGE and silver staining. The addition of calpain inhibitors during the purification procedure was critical for limiting proteolysis and thus stabilizing the native enzyme Takazawa et al., 1990a) , as calpain has been shown to be a major neutral protease in the cytosol of human platelets (Truglia and Stracjer, 1981; Tsujinaka et al., 1982) . Moreover, the use of one-step chromatography also limited proteolysis during purification of InsP3 3-kinase activity. Biochemical data for the human platelet InsP3 3-kinase show that the platelet enzyme is quite distinct from the rat brain Mr-50000 InsPJ 3-kinase A (Takazawa et al., 1990a,b) . (1) The human platelet InsPJ 3-kinase presented a higher molecular mass (see above). (2) The stimulation factor by Ca2+/CaM was higher for the human platelet enzyme than for the rat brain protein, approx. 17-fold and 4-fold respectively, at saturating CaM. (3) The human platelet enzyme was not recognized by anti-(Mr-50000 rat brain InsP3 3-kinase A) antibodies. (4) It was also not recognized by immunodetection using antibodies prepared against the N-terminal region of human InsP. 3-kinase A.
Since the human platelet InsP3 3-kinase had a higher molecular mass, which may be comparable with that of human InsP3 3-kinase B, we questioned whether the platelet enzyme would be either InsP3 3-kinase B or a novel form. It was observed that the platelet enzyme was not recognized by specific anti-(Mr-63000 human InsP3 3-kinase B) antibodies. Our data therefore suggest the presence of a novel high-molecular-mass isoenzyme in human platelets which is distinct from InsP3 3-kinase isoenzymes A and B. Lin et al. (1993) recently reported the purification of a major active Mr-36000 polypeptide in human platelets. They obtained a low specific activity (283 nmol/min per mg at saturating CaM) and a low yield of purification (16 %). As discussed by Lin et al. (1993) , the Mr-36000 polypeptide probably resulted from proteolysis of a higher-molecular-mass InsP3 3-kinase. We could speculate that the Mr-36000 polypeptide could be the catalytic domain of the platelet enzyme, as proteolysis of the rat brain enzyme yielded an active polypeptide in the same molecularmass range (Takazawa et al., 1990a) .
A simple model which accounts for the enhancement of InsP3 3-kinase activity upon exposure of human platelets to thrombin would be a direct stimulation of the enzyme by Ca2+ (Daniel et al., 1987) . However, in addition to Ca2+, human platelet InsP3 3-kinase can be shown to be a substrate of protein kinase C. This has been studied both directly, on purified enzyme (D. Communi, M. Rider and C. Erneux, unpublished work; Lin et al., 1990) , and indirectly, by treatment of human platelets with the protein kinase C agonist ,-phorbol 12,13-dibutyrate (King and Rittenhouse, 1989) . It is therefore possible that InsP3 3-kinase activity may be modulated by intracellular Ca2+ levels, as shown for the CaM-sensitive cyclic nucleotide phosphodiesterase (Erneux et al., 1985) and, in addition, may be regulated by phosphorylation/ dephosphorylation mechanisms. Further studies are required to elucidate these mechanisms.
